Loading patent…
AssigneeYale University
InventorsChristopher Breuer, Tarek Fahmy, Michael Simons, Pei-Yu Chen, Daniel Rowe Duncan, Joseph Patterson
Estimating the term…
Methods for treating or preventing neointima stenosis are disclosed. The methods generally involve the use of a TGFβ inhibitor, a SMAD2 inhibitor, an FGF Receptor agonist, a Let-7 agonist, or a combination thereof, to inhibit endothelial-to-mesenchymal transition (Endo-MT) of vascular endothelial cells into smooth muscle cells (SMC) at sites of endothelial damage. The disclosed methods can therefore be used to prevent or inhibit neointimal stenosis or restenosis, e.g., after angioplasty, vascular graft, or stent. Also disclosed are methods for increasing the patency of biodegradable, synthetic vascular grafts using a composition that inhibits Endo-MT. A cell-free tissue engineered vascular graft (TEVG) produced by this method is also disclosed.
A method for treating or preventing neointimal stenosis in a subject, comprising administering to the subject a pharmaceutical composition comprising a TGFβ inhibitor, a SMAD2 inhibitor, an FGF Receptor agonist, a Let-7 agonist, or a combination thereof.
A method for increasing the patency of a polymeric vascular graft comprising administering to the graft an effective amount of a composition comprising a TGFβ inhibitor, a SMAD2 inhibitor, an FGF Receptor agonist, a Let-7 agonist, or a combination thereof.
A cell-free polymeric vascular graft comprising an effective amount of a TGFTGFβ inhibitor, a SMAD2 inhibitor, an FGF Receptor agonist, a Let-7 agonist, or a combination thereof, to increase the recruitment of host cells to the graft relative to the graft without the TGFβ inhibitor, a SMAD2 inhibitor, an FGF Receptor agonist, a Let-7 agonist, or a combination thereof.
Dependencies are inferred from the claim text.